Loargys-Pegzilarginase-Nbln
Loargys (pegzilarginase-nbln) is indicated for the treatment of Arginase 1 Deficiency (ARG1-D), also known as hyperargininemia, in adult and pediatric patients 2 years of age and older, a rare urea cycle disorder characterized by elevated plasma arginine levels and progressive neurological impairment. Loargys functions as an enzyme replacement therapy, reducing toxic arginine accumulation and helping […]
Keytruda Qlex-Pembrolizumab And Berahyaluronidase Alfa-Pmph
Keytruda Qlex is an FDA-approved subcutaneous formulation of Keytruda developed by Merck & Co. It contains the active immunotherapy molecule pembrolizumab, a PD-1 immune checkpoint inhibitor, combined with berahyaluronidase alfa, an enzyme that enables rapid subcutaneous delivery. Unlike the traditional intravenous (IV) infusion of Keytruda administered over 30 minutes, Keytruda Qlex is given as a […]
Yartemlea-Narsoplimab-Wuug
Yartemlea is a fully human monoclonal antibody that selectively inhibits mannan-binding lectin–associated serine protease-2 (MASP-2), a key enzyme in the lectin pathway of the complement system. It is approved for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA) in adults and pediatric patients aged two years and older. By blocking MASP-2, Yartemlea prevents […]
Lerochol-Lerodalcibep-Liga
Lerochol is a novel cholesterol-lowering biologic developed to address unmet needs in the management of hypercholesterolemia. It is indicated as an adjunct to diet and exercise for reducing low-density lipoprotein cholesterol (LDL-C) levels in adults, including those with heterozygous familial hypercholesterolemia (HeFH). It is designed to target PCSK9-mediated pathways, thereby enhancing LDL receptor recycling and […]
Exdensur-Depemokimab-Ulaa
Exdensur (depemokimab-ulaa) is an ultra-long-acting biologic therapy indicated as an add-on maintenance treatment for severe asthma with an eosinophilic phenotype in adults and adolescents aged 12 years and older. It is administered as a subcutaneous injection every six months in addition to standard asthma medications to help reduce the frequency of asthma exacerbations. It is […]
Voyxact Sibeprenlimab-Szsi
Voyxact® (sibeprenlimab-szsi) is an FDA-approved prescription medicine used to reduce proteinuria (protein in the urine) in adults with primary IgA nephropathy (IgAN) who are at risk of disease progression. This approval is under the FDA’s accelerated approval pathway, based on the reduction of proteinuria. Its long-term impact on slowing kidney function decline is still being […]
Elfabrio-Pegunigalsidase Alfa-Iwxj
Elfabrio is the first PEGylated enzyme replacement therapy approved by the FDA for adults with Fabry disease. It provides exogenous alpha‑galactosidase A to reduce globotriaosylceramide accumulation and improve organ function.
Epkinly-Epcoritamab-Bysp
Epkinly is an injection used for certain types of blood cancer like large B-cell lymphoma. It helps immune cells find and destroy cancer cells.
Leqembi-Lecanemab-Irmb
Leqembi is a prescription medicine for early-stage Alzheimer’s disease. It’s a monoclonal antibody that helps reduce amyloid plaques in the brain and is the first treatment of its kind approved in the European Union.
Zynyz-Retifanlimab-Dlwr
Zynyz is the first PD‑1 inhibitor approved by the FDA for adult patients with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal canal. It is now available both as monotherapy and in combination with platinum‑based chemotherapy, and is also approved for metastatic Merkel cell carcinoma; it enhances T‑cell activity to target and […]
